These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 8833831)

  • 21. Susceptibility to Yersinia pseudotuberculosis infection is linked to the pattern of macrophage activation.
    Tansini A; de Medeiros BM
    Scand J Immunol; 2009 Apr; 69(4):310-8. PubMed ID: 19284495
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Yersinia pseudotuberculosis infection in children. Clinical manifestations and epidemiology.
    Sato K
    Contrib Microbiol Immunol; 1987; 9():111-6. PubMed ID: 3311631
    [No Abstract]   [Full Text] [Related]  

  • 23. [Yersinia pseudotuberculosis infection].
    Takeda N
    Ryoikibetsu Shokogun Shirizu; 1999; (23 Pt 1):496-9. PubMed ID: 10088455
    [No Abstract]   [Full Text] [Related]  

  • 24. Characterization of a superantigen produced by Yersinia pseudotuberculosis.
    Abe J; Takeda T
    Prep Biochem Biotechnol; 1997; 27(2-3):173-208. PubMed ID: 9292925
    [No Abstract]   [Full Text] [Related]  

  • 25. Superantigen antagonist protects against lethal shock and defines a new domain for T-cell activation.
    Arad G; Levy R; Hillman D; Kaempfer R
    Nat Med; 2000 Apr; 6(4):414-21. PubMed ID: 10742148
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Yersinia pseudotuberculosis infection in the mountain area.
    Inoue M; Nakashima H; Mori T; Sakazaki R; Tamura K; Tsubokura M
    Contrib Microbiol Immunol; 1991; 12():307-10. PubMed ID: 1935109
    [No Abstract]   [Full Text] [Related]  

  • 27. [A seroepidemiological survey of the natural infection of pseudotuberculosis in human beings and animals].
    Li XF
    Zhonghua Liu Xing Bing Xue Za Zhi; 1987 Feb; 8(1):40-2. PubMed ID: 3304653
    [No Abstract]   [Full Text] [Related]  

  • 28. [Bacterial enterotoxins bearing superantigenic properties].
    Miyoshi-Akiyama T; Uchiyama T
    Nihon Saikingaku Zasshi; 1995; 50(2):501-8. PubMed ID: 7623416
    [No Abstract]   [Full Text] [Related]  

  • 29. Th1-type immune response to infection by pYV-cured phoP-phoQ null mutant of Yersinia pseudotuberculosis is defective in mouse model.
    Kumar S; Balakrishna K; Agarwal GS; Merwyn S; Rai GP; Batra HV; Sardesai AA; Gowrishankar J
    Antonie Van Leeuwenhoek; 2009 Jan; 95(1):91-100. PubMed ID: 18985430
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protection against Yersinia pseudotuberculosis infection conferred by a Lactococcus lactis mucosal delivery vector secreting LcrV.
    Daniel C; Sebbane F; Poiret S; Goudercourt D; Dewulf J; Mullet C; Simonet M; Pot B
    Vaccine; 2009 Feb; 27(8):1141-4. PubMed ID: 19135495
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Pseudotuberculosis in the Krasnodar Territory. The clinico-epidemiological characteristics of its morbidity and the biological properties of its strains].
    Zaĭdenov AM; Morozov AA; Kostiukovskiĭ VM; Gurleva GG; Brudnyĭ RA; Kalashnikov IA; Blagorodova NS; Nagornaia AF; Kutishevskaia EF; Kucheriavaia IE
    Zh Mikrobiol Epidemiol Immunobiol; 1991 Apr; (4):26-8. PubMed ID: 1831948
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outbreak of Yersinia pseudotuberculosis in British Columbia--November 1998.
    Nowgesic E; Fyfe M; Hockin J; King A; Ng H; Paccagnella A; Trinidad A; Wilcott L; Smith R; Denney A; Struck L; Embree G; Higo K; Chan JI; Markey P; Martin S; Bush D
    Can Commun Dis Rep; 1999 Jun; 25(11):97-100. PubMed ID: 10726370
    [No Abstract]   [Full Text] [Related]  

  • 33. [Group disease in children caused by enteroviruses and Yersinia].
    Frolov AF; Zadorozhnaia VI; Bondarenko VI; Tolnina ZA; Fedorov ON; Siniak LI; Prikhod'ko EF
    Vrach Delo; 1991 Jul; (7):92-5. PubMed ID: 1663297
    [No Abstract]   [Full Text] [Related]  

  • 34. Pathogenic role of a superantigen in Yersinia pseudotuberculosis infection.
    Abe J; Kano H; Nogami H; Matsumoto S; Baba K; Saito H; Kohsaka T
    Adv Exp Med Biol; 2003; 529():459-61. PubMed ID: 12756809
    [No Abstract]   [Full Text] [Related]  

  • 35. Streptococcus pyogenes: Insight into the function of the streptococcal superantigens.
    Sriskandan S; Faulkner L; Hopkins P
    Int J Biochem Cell Biol; 2007; 39(1):12-9. PubMed ID: 17029999
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Colonic epithelial physiology is altered in response to the bacterial superantigen Yersinia pseudotuberculosis mitogen.
    Donnelly GA; Lu J; Takeda T; McKay DM
    J Infect Dis; 1999 Nov; 180(5):1590-6. PubMed ID: 10515820
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Prevalence of anti-Yersinia antibodies in European brown hares in North-Rhine Westphalia, Germany].
    Bartling C; Wölfel R; Nikolaou K; Petry T; Thiede S; Hildebrandt T; Fassbender M; Göritz F; Blottner S; Spittler H; Neubauer H
    Dtsch Tierarztl Wochenschr; 2004 Jun; 111(6):259-60, 262-4. PubMed ID: 15287580
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Yop effector proteins from Yersinia pseudotuberculosis impair dendritic cell activation.
    Tansini A; da Silva FF; Dos Santos RR; Placeres MC; de Medeiros BM; Carlos IZ
    Adv Exp Med Biol; 2012; 954():203-8. PubMed ID: 22782764
    [No Abstract]   [Full Text] [Related]  

  • 39. Seroepidemiologic study on the occurrence of antibodies against Yersinia enterocolitica and Yersinia pseudotuberculosis in urban and rural population of the Lublin region (eastern Poland).
    Stojek NM
    Ann Agric Environ Med; 1999; 6(1):57-61. PubMed ID: 10384217
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular epidemiology of Yersinia pseudotuberculosis.
    Fukushima H
    Adv Exp Med Biol; 2003; 529():357-8. PubMed ID: 12756788
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.